BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10739874)

  • 1. The effect of side-chain, para-aminobenzoyl region, and B-ring modifications on dihydrofolate reductase binding, influx via the reduced folate carrier, and cytotoxicity of the potent nonpolyglutamatable antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L- ornithine.
    Rosowsky A; Wright JE; Vaidya CM; Forsch RA
    Pharmacol Ther; 2000 Mar; 85(3):191-205. PubMed ID: 10739874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
    Chen G; Wright JE; Rosowsky A
    Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PT523 and other aminopterin analogs with a hemiphthaloyl-L-ornithine side chain: exceptionally tight-binding inhibitors of dihydrofolate reductase which are transported by the reduced folate carrier but cannot form polyglutamates.
    Rosowsky A
    Curr Med Chem; 1999 Apr; 6(4):329-52. PubMed ID: 10101216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analogues of N alpha-(4-amino-4-deoxypteroyl)-N delta-hemiphthaloyl-L-ornithine (PT523) modified in the side chain: synthesis and biological evaluation.
    Rosowsky A; Vaidya CM; Bader H; Wright JE; Teicher BA
    J Med Chem; 1997 Jan; 40(3):286-99. PubMed ID: 9022795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient utilization of the reduced folate carrier in CCRF-CEM human leukemic lymphoblasts by the potent antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L- ornithine (PT523) and its B-ring analogues.
    Wright JE; Vaidya CM; Chen Y; Rosowsky A
    Biochem Pharmacol; 2000 Jul; 60(1):41-6. PubMed ID: 10807943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
    Rosowsky A; Bader H; Wright JE; Keyomarsi K; Matherly LH
    J Med Chem; 1994 Jul; 37(14):2167-74. PubMed ID: 8035423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and in vitro antitumor activity of new deaza analogues of the nonpolyglutamatable antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine (PT523).
    Vaidya CM; Wright JE; Rosowsky A
    J Med Chem; 2002 Apr; 45(8):1690-6. PubMed ID: 11931624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphthaloyl- L-ornithine (PT523).
    Rosowsky A; Wright JE; Vaidya CM; Bader H; Forsch RA; Mota CE; Pardo J; Chen CS; Chen YN
    J Med Chem; 1998 Dec; 41(26):5310-9. PubMed ID: 9857098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further studies on the interaction of nonpolyglutamatable aminopterin analogs with dihydrofolate reductase and the reduced folate carrier as determinants of in vitro antitumor activity.
    Wright JE; Yurasek GK; Chen YN; Rosowsky A
    Biochem Pharmacol; 2003 May; 65(9):1427-33. PubMed ID: 12732354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
    Rhee MS; Galivan J; Wright JE; Rosowsky A
    Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analogues of the potent nonpolyglutamatable antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine (PT523) with modifications in the side chain, p-aminobenzoyl moiety, or 9,10-bridge: synthesis and in vitro antitumor activity.
    Rosowsky A; Wright JE; Vaidya CM; Forsch RA; Bader H
    J Med Chem; 2000 Apr; 43(8):1620-34. PubMed ID: 10780919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate analogues. 33. N delta-acyl-N alpha-(4-amino-4-deoxypteroyl)-L-ornithine derivatives: synthesis and in vitro antitumor activity.
    Rosowsky A; Bader H; Cucchi CA; Moran RG; Kohler W; Freisheim JH
    J Med Chem; 1988 Jul; 31(7):1332-7. PubMed ID: 3385730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes reduced with nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523.
    Cody V; Galitsky N; Luft JR; Pangborn W; Rosowsky A; Blakley RL
    Biochemistry; 1997 Nov; 36(45):13897-903. PubMed ID: 9374868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
    Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
    Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMR solution structure of the antitumor compound PT523 and NADPH in the ternary complex with human dihydrofolate reductase.
    Johnson JM; Meiering EM; Wright JE; Pardo J; Rosowsky A; Wagner G
    Biochemistry; 1997 Apr; 36(15):4399-411. PubMed ID: 9109647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and in vitro biological activity of new deaza analogues of folic acid, aminopterin, and methotrexate with an L-ornithine side chain.
    Rosowsky A; Forsch RA; Bader H; Freisheim JH
    J Med Chem; 1991 Apr; 34(4):1447-54. PubMed ID: 2016722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway.
    Zhao R; Hanscom M; Chattopadhyay S; Goldman ID
    Cancer Res; 2004 May; 64(9):3313-9. PubMed ID: 15126375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological activity of methotrexate analogues with two acid groups and a hydrophobic aromatic ring in the side chain.
    Rosowsky A; Bader H; Freisheim JH
    J Med Chem; 1991 Feb; 34(2):574-9. PubMed ID: 1995880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, antifolate activity and tissue distribution of PT523 in SCC VII tumor-bearing mice.
    Wright JE; Pardo M; Tretyakov A; Alperin WL; Trites D; Rosowsky A
    Cancer Chemother Pharmacol; 1998; 42(4):300-6. PubMed ID: 9744775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.